Podcasts about expert perspectives

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion In this podcast article, the authors share their perspectives on current treatment for the rare, locally aggressive neoplasm, tenosynovial giant cell tumor (TGCT). They also discuss the patient care journey in the US, and highlight the clinical significance of the MANEUVER study findings. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03725-x. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Send us Fan MailArizona's family law just changed dramatically. In this roundtable, Modern Law's Richard Nedlin and Gina Godbehere — both former prosecutors — break down the Alec & Lydia Act (HB 2995) and what it means for parents navigating domestic violence allegations, custody, and legal decision-making in family court.We cover the new burden-shifting standards, what "coercive control" really means, and how courts will handle presumptions against parenting time. If you have a case touching on this new law, don't navigate it alone.Richard and Gina are taking consultations now  - Book below, visit www.mymodernlaw.com or call us at Call 480-649-2905 https://app.acuityscheduling.com/schedule/c941efa0/?categories%5B%5D=Modern%20Law%25%E2%80%A6 #AlecAndLydiaAct #ArizonaFamilyLaw #DomesticViolenceAwareness #ChildCustody #ModernLaw

This episode explores how soccer and the World Cup connect with geopolitics, international relations, and global influence. Dr. Gonzalo Bravo talks with Andrés Martínez, the co-director of The Great Game Lab at Arizona State University, where he also serves as a special advisor to the university president. His work explores the global convergence of sport, media, and geopolitics. Previously he served as editorial page editor of the Los Angeles Times and assistant editorial page editor at The New York Times, where he was a finalist for the Pulitzer Prize. He is the author of The Great Game: A Tale of Two Footballs and America's Quest to Conquer Global Sport, published in early April this year. 

This episode features an in-depth discussion on the planning, logistics, and science that drive successful mega sporting events like the 2026 FIFA World Cup. Dr. Gonzalo Bravo talks with John Terry, Vice President of Events at U.S. Soccer Federation. He oversees coordination of event operations for U.S. Men's and Women's National Team matches, including venue operations, field/turf management, security, and facility operations. He earned both his Bachelor's and master's degrees in Sport Management from West Virginia University.

This episode features a discussion on how innovation and artificial intelligence are shaping the future of fairness and decision-making during the World Cup. Dr. Gonzalo Bravo talks with Juan Jose “Cheche” Vidal, a pioneer in the application of technology in the FIFA World Cup. He served as Vice President for Technology during the USA 1994 World Cup. A former NCAA and Olympian soccer player, he attended Boston University on athletic scholarship, earning a bachelor's degree in mechanical engineering and a master's degree in Biomechanics and Technology Applied to Sports.

This episode features a behind-the-scenes look at media operations and communication strategies at the highest level of international sport. Dr. Gonzalo Bravo talks with Rob De Leede, a professor of public relations and communications at The Hague University of Applied Sciences in the Netherlands. He previously served as press officer for the Dutch National Team (1995–2004) as well as media officer for FIFA and UEFA. He has covered multiple FIFA World Cups and UEFA European Championships. 

If you're in the middle of trying to figure out what to do about your back pain, whether that means researching your diagnosis, weighing surgical options, or trying to understand what recovery actually looks like, this episode was made for you. We've done something a little different with this one... We went back through some of our most powerful conversations and pulled the moments that matter most for patients at exactly this stage of their journey. Think of it as a "greatest hits", built around the questions we hear most often, and the answers that have resonated most with our listeners over time. You'll hear from VSI spine surgeons like Dr. Christopher Good and Dr. Ehsan Jazini on what a surgical consultation should look like, and why so many patients end up making decisions without the full picture. You'll also hear from Dr. Colin Haines, Dr. Niteesh Bharara, and Dr. Yash Mehta on why pain persists, what it's actually telling you, and when it's time to stop waiting for it to 'get better'. And you'll hear from one of our Physician Assistants as well as two patients, Rachel and Nick, on what the other side of spine surgery recovery really looks like. By the end of this episode, you'll have a clearer sense of the questions worth asking, the options worth exploring, and what it actually means to go into a spine surgery decision , and your recovery, feeling prepared. If any of these conversations resonate with you, we'd encourage you to go deeper. Links to the full YouTube video episodes with every doctor and patient featured today are below: On Pain Relief:  Dr. Haines Says, "It's Not Normal to Hurt": Episode 70 Dr. Bharara Shares the Risks of Pushing Through Pain: Episode 85 Dr. Mehta's Tips for Lasting Back Pain Relief: Episode 75 On Spine Surgery: Dr. Jazini & Dr. Good on Pain After a Prior Surgery: Episode 76 Dr. Good Explains Spinal Fusion vs. Disc Replacement: Episode 37 Dr. Jazini Shares the Importance of an Individualized Approach: Episode 58 VSI Surgical Team Gets Real about Preparing for Surgery: Episode 65  On Spine Surgery Recovery: Dr. Good on How to Accelerate Recovery: Episode 82 Nick's Disc Replacement Journey: Episode 86 Rachel's Disc Replacement Recovery: Episode 84   Watch the video version of this epiosde on Youtube: https://youtu.be/2DN2URL4mUs?si=DW2hKiavZRPXa0BL Read the adjoining blog: https://www.spinemd.com/resources/podcasts/the-back-pain-roadmap-from-experts/ Ready to explore your options? Visit VSIspine.com to schedule a consultation with a spine specialist who can discuss an individualized treatment plan to help you overcome your neck and back pain.  ❤️ Love this episode? Rate & Review this podcast to let us know your honest feedback.

In this podcast, experts Tiffany A. Traina, MD, FASCO, Kevin Kalinsky, MD, MS, FASCO, Mark E. Robson, MD, FASCO, and Rebecca Shatsky, MD discuss data for CDK4-6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors in the management of early-stage hormone receptor-positive, HER-2-negative breast cancer.

In this podcast, experts Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD, discuss frontline, second-line, and antibody-drug conjugate therapies for the treatment of HR-positive, HER2-negative metastatic breast cancer.

Featuring perspectives from Dr Yelena Y Janjigian, including the following topics: Introduction (0:00) Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20) Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53) Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55) Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18) Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28) Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54) CME information and select publications

Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.CME information and select publications here.

Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.CME information and select publications here.

Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.CME information and select publications here.

The International Equestrian Federation (FEI) has changed the so-called Blood Rule in show jumping – sparking debate throughout the equestrian world. This rule concerns how to handle situations in competitions where blood is detected on a participating horse before, during, or after a test. From the date the new regulation comes into force on January 1, 2026, horses will still be able to participate in the competition under certain circumstances despite visible blood, for example in a second round of a Grand Prix or a jump-off. What does this mean for equestrian sport? Why did the FEI General Assembly reach this voting result? And why do many experts see it as a step backward for animal welfare? In this episode, we explore these and other questions together with two insiders who both hold positions within the FEI: veterinarian Dr. Michael Köhler and judge Joachim Geilfus. They explain: • how the controversial vote came about – and why each nation only has one vote • what scenarios could arise at future competitions • what new responsibilities now lie with judges and veterinarians • why they view the rule change critically and what effects they expect An episode for anyone who wants to understand what happens behind the scenes of international sport – and what the decision means for horses, riders and trust in the sport. *Important to note: This podcast episode was originally recorded in German for the wehorse podcast. We used translation software to dub the episode for our English podcast, The Equestrian Connection.

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy. Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu

In this AANEM session, Chilvana Patel, MD moderates a discussion with Pushpa Narayanswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD on the evolving treatment landscape in myasthenia gravis (MG). The panel reviews the use of targeted therapies in women of childbearing age with myasthenia gravis, alongside guidance for perioperative care before elective surgery. Through illustrative patient cases, the experts provide insight into practical challenges and emerging opportunities in tailoring advanced immunotherapies to individual patient needs.

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:  Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00) Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42) Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn's disease — Neil Morganstein, MD (17:48) Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14) Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15) Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09) CME information and select publications

Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here.

Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here.

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics:  Introduction (0:00) Case 1: Adjuvant Systemic Therapy? (1:15) Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16) Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54) Case 4: Trilaciclib in Extensive-Stage Disease (13:50) Comments: ASCO and Other Recent Datasets (18:05) Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34) Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33) Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54) Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38) CME information and select publications

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.

Chilvana Patel, MD is hosting a case-based panel discussion titled "Evolving Therapeutic Horizons in Myasthenia Gravis: Expert Perspectives on Targeted Therapies - Part 1." She will engage with renowned neuromuscular specialists—Pushpa Narayanaswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD—to explore real-world cases and discuss the latest advances in targeted treatment options for Myasthenia Gravis.

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics: Introduction: ASCO Preview (0:00) HER2-Positive Gastroesophageal Cancers (19:03) Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11) Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04) CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30) CME information and select publications

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

In this Medical Affairs unscripted Podcast Byte, Peg Crowley-Nowick, PhD, MBA, President of Medical Affairs Consulting at Lumanity, discusses the recently released insights report: Expert Perspectives on the Use of Generative AI in Medical Publication with her colleague, Tim Becker, PharmD, RPh, EVP, Creative Scientific Solutions at Lumanity. Their discussion sheds light on the safe and proper use of Generative AI in medical publications, addressing key concerns such as hallucinations, data privacy, and the need for transparency and accountability. They also explore the future impact of Generative AI on medical communication agencies and their relationships with journals. Although Generative AI can accelerate the delivery of data to patients and healthcare providers, it will still require the careful oversight of trained professionals to ensure ethical and appropriate use. 

Today on the Clean Power Hour, Tim Montague sits down with Eric Goodwin, Vice President of Business Development at OMCO Solar, to explore the evolution and future of solar manufacturing in the United States. From its roots as a truck bumper manufacturer in 1955 to becoming America's largest custom roll former with 13GW of annual solar racking capacity, OMCO's story exemplifies the transformation of US manufacturing in the renewable energy era.Eric shares invaluable insights into OMCO's journey from a contract manufacturer for other racking companies to developing their own innovative product line, including fixed-tilt and tracker solutions. The conversation goes deep into the impact of the Inflation Reduction Act, domestic content requirements, and how OMCO achieves 88-92% domestic content in their products. Listeners will learn about OMCO's exciting partnership with Create Energy, founded by industry pioneer Dean Solon (founder of Shoals Technologies), and their shared vision for advancing US solar manufacturing.We also discussed our upcoming exclusive webinar featuring OMCO Solar, Sunstall, and Obodo Energy on Jan 23, 1 PM Eastern, Noon Central, 11 AM Mountain, and 10 AM Pacific! Eric Goodwin and Matt Kessler from OMCO Solar, Helge Biernath, CEO of Sunstall, and John Mitman, CEO of Obodo Energy, will share their insights on handling project changes, adapting to unexpected site conditions, managing supply chain disruptions, and implementing module changes mid-installation with minimal impact. Learn from their years of successful collaboration and discover how strong partnerships can drive project success even in challenging circumstances. This webinar will showcase practical examples and strategies that have helped their teams deliver successful solar installations while minimizing change orders and project delays. Register here for the webinar.Don't miss this comprehensive discussion about one of the most critical components of utility-scale and distributed-generation solar projects.Social Media HandlesOMCO Solar WebinarEric GoodwinOMCO Support the showConnect with Tim Clean Power Hour Clean Power Hour on YouTubeTim on TwitterTim on LinkedIn Email tim@cleanpowerhour.com Review Clean Power Hour on Apple PodcastsThe Clean Power Hour is produced by the Clean Power Consulting Group and created by Tim Montague. Contact us by email: CleanPowerHour@gmail.com Corporate sponsors who share our mission to speed the energy transition are invited to check out https://www.cleanpowerhour.com/support/The Clean Power Hour is brought to you by CPS America, maker of North America's number one 3-phase string inverter, with over 6GW shipped in the US. With a focus on commercial and utility-scale solar and energy storage, the company partners with customers to provide unparalleled performance and service. The CPS America product lineup includes 3-phase string inverters from 25kW to 275kW, exceptional data communication and controls, and energy storage solutions designed for seamless integration with CPS America systems. Learn more at www.chintpowersystems.com

In the world of commercial real estate, gaining financial freedom isn't just a dream—it's an achievable goal. As discussed by host Jonathan Hayek and guest Jay Conner in this insightful episode of the Scott Paton Podcast, understanding the intricate details of raising capital, fostering meaningful relationships, and having a strategic investment approach are pivotal for success.Raising Capital for Real EstateOne of the first steps towards achieving financial freedom in commercial real estate involves raising capital. Jonathan Hayek highlights that while familiarity with real estate can be beneficial, it's not strictly necessary. Interestingly, his initial deal was made possible by borrowing $110,000 from a contact named Ryan via a self-directed IRA, and another $50,000 from a friend. This emphasizes that leveraging personal networks can be an effective strategy for securing funds.Moreover, having a proven track record can significantly attract private money lenders. Hayek himself leveraged a mix of funding sources which included private money, hard money, balance transfers from credit cards, and local banks. He stresses the importance of presenting specific deals with clear terms to potential investors rather than vague promises of future opportunities.Strategic Investment ApproachesBoth Jonathan Hayek and Jay Conner emphasize a non-aggressive approach when it comes to finding investors. Rather than chasing or begging for money, they advocate for building genuine relationships. Hayek stresses the importance of attracting investors who are confident, financially secure, and a good fit for the deal.Straightforwardly presenting investment opportunities is crucial. It promotes trust and clarity, which, in turn, can lead to successful, long-term investment partnerships. A critical takeaway from their discussion is that the quality of investors often outweighs the quantity.Growing Mindset and Overcoming Limiting BeliefsJonathan Hayek's journey from being a special education teacher and non-profit worker to a full-time real estate investor underscores the importance of personal growth and overcoming limiting beliefs. He shares how he realized the need for greater financial growth and decided to pursue bigger goals.One of Hayek's personal growth strategies involves adopting mantras like "You're Not Thinking Big Enough." He encourages listeners to challenge deeply ingrained beliefs, many of which are rooted in childhood, to achieve their true potential. This mindset shift enabled him to leave his job and fully commit to real estate, exploring non-traditional opportunities such as industrial deals.Building a Sustainable BusinessA key insight from this episode is the concept of "rightsizing" your business to fit individual, family, and lifestyle needs, as discussed by Jay Conner. Jonathan Hayek emphasizes understanding one's "why" in real estate to avoid the pervasive pressure of constant scaling driven by social media influences. Bigger isn't always better; the focus should be on creating a business that aligns with personal goals, whether it's spending more time with family or enjoying freedom.The Power of Networks and ReferralsTrust and relationships are central to raising private money. Jay Conner and Jonathan Hayek both highlight that investors essentially invest in the person, based on reliability and trustworthiness. Jonathan's network of lenders is primarily based on established relationships with friends and family, leveraging their faith in his ability to manage their investments securely.Additionally, referrals play a crucial role. By delivering successful deals, Jonathan and Jay have benefited from referrals from existing lenders, further broadening their network and enhancing their investment opportunities.Real Estate Investment StrategiesJonathan Hayek has a focused app

Election fever is heating up, and no matter how you plan on voting, these 3 Takeaways excerpts provide valuable insight into our political challenges, plus thoughts on how to resolve them. Guests include Yale Law School Professor Amy Chua; former political consultant and presidential advisor Karl Rove; White House advisor to four U.S. presidents David Gergen; political commentator and Pulitzer Prize-winning columnist George Will; and journalist extraordinaire Fareed Zakaria.

Join Kailin Noivo as he chats with Jesse Hanse, the Head of E-commerce at Paula's Choice, in this episode of the E-commerce Toolbox podcast. Alongside insights on adopting a composability strategy and the future initiatives at Paula's Choice, Jesse explains the importance of content and education in their D2C skincare brand and how they are re-architecting their website to enhance the customer experience.

Innovation and disruption are constants in the supply chain game. In this episode, hosts Scott W. Luton and Kevin L. Jackson, alongside special guests Greg Buzek from IHL Group and Vignesh Balasubramanian from Microsoft, dive deep into the pivotal role of generative AI in revolutionizing supply chain management. Understand the significant inefficiencies in current transportation logistics, with over 50% of trucks less than half full, and how AI can turn this challenge into a substantial efficiency gain. Our experts share real-world applications from Microsoft, highlighting AI's role in enhancing planning and forecasting capabilities, adapting to changing data, and optimizing logistics to cut costs and improve delivery times. Vignesh's personal anecdotes from the COVID-19 pandemic illustrate the importance of preparedness and strategic adaptation in the face of geopolitical and weather-related disruptions.Looking toward the future, we discuss strategies like nearshoring, the lasting impact of supply chain disruptions on inflation and consumer experiences, and the critical importance of maintaining clean and ready data for AI optimization. Gain valuable insights, practical strategies, and a compelling call to action to embrace AI-driven innovations to stay competitive in today's volatile market.Additional Links & Resources:Enhancing Service Excellence with AI: Unleashing Microsoft Dynamics 365 for ERP: https://bit.ly/3RtPMbMCommitment to Security- Microsoft Build 2024: https://bit.ly/4c5OdIKLearn more about Supply Chain Now: https://supplychainnow.comSubscribe to Supply Chain Now: https://supplychainnow.com/joinCheck out Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkWEBINAR- How to Accelerate AI-Driven Decision Intelligence with Smart Data Fabric: https://bit.ly/3QMPmgaWEBINAR- Automation ROI: Solving the Top 3 Operational Challenges: https://bit.ly/3VvxTvsWEBINAR- Strategies for Aligning Business Planning with Supply Chain Design: https://bit.ly/3XvRHk7This episode is hosted by Scott Luton and Kevin L. Jackson. For additional information, please visit our dedicated show page at: https://supplychainnow.com/unveiling-supply-chain-innovation-deep-dive-expert-perspectives-microsoft-1287